Q32 Bio Inc (QTTB)
NASDAQ:QTTB
Top Page
Q32 Bio
(NASDAQ:QTTB)
Select Model
Select Model
Rating:58Neutral
Price Target:
$6.50
▲(6.38% Upside)
Action:ReiteratedDate:03/28/26
The score is held back primarily by weak financial performance (effectively zero recent revenue and continued cash burn), despite improved balance sheet metrics. Technicals are a key offset, showing a strong uptrend with positive momentum, while valuation appears optically cheap but is less dependable given volatile earnings quality. Recent financings add funding flexibility but also raise dilution risk.
Positive Factors
Balance sheet repair
The company materially reduced leverage and rebuilt equity in 2025, lowering financial strain versus prior years. This reduction in debt and large equity infusion improves near-term solvency, extends runway and decreases refinancing urgency, supporting continued R&D investment over multiple quarters.
Negative Factors
Persistent cash burn
Despite improvement, operating cash flow remains deeply negative and free cash flow deteriorated on a growth basis in 2025. Continued cash burn forces dependence on external financing and constrains the company's ability to self-fund operations or scale programs without dilutive capital raises in the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet repair
The company materially reduced leverage and rebuilt equity in 2025, lowering financial strain versus prior years. This reduction in debt and large equity infusion improves near-term solvency, extends runway and decreases refinancing urgency, supporting continued R&D investment over multiple quarters.
Read all positive factors
Q32 Bio (QTTB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$89.39M
Dividend YieldN/A
Average Volume (3M)277.10K
Price to Earnings (P/E)0.2
Beta (1Y)0.59
Revenue GrowthN/A
EPS Growth49.57%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)4.58
Shares Outstanding14,629,463
10 Day Avg. Volume357,127
30 Day Avg. Volume277,103
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.69
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue0.77
Enterprise Value/Gross Profit0.77
Enterprise Value/Ebitda2.17
Forecast
1Y Price Target
$14.33Price Target Upside134.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Q32 Bio Business Overview & Revenue Model
Company Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead p...
How the Company Makes Money
null...
Q32 Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 53.74M | 0.00 | -6.65M | 6.65M | 33.97M |
| Gross Profit | 53.35M | -487.00K | -6.65M | 6.65M | 24.43M |
| EBITDA | 17.29M | -45.30M | -47.76M | -38.85M | -86.22M |
| Net Income | 29.82M | -47.73M | -53.74M | -42.81M | -95.76M |
Balance Sheet | |||||
| Total Assets | 61.78M | 92.33M | 47.06M | 61.77M | 211.72M |
| Cash, Cash Equivalents and Short-Term Investments | 48.30M | 77.97M | 25.62M | 43.89M | 155.87M |
| Total Debt | 15.34M | 18.90M | 50.84M | 44.73M | 23.93M |
| Total Liabilities | 19.76M | 86.66M | 229.98M | 192.49M | 42.07M |
| Stockholders Equity | 42.01M | 5.67M | -182.92M | 177.98M | 169.65M |
Cash Flow | |||||
| Free Cash Flow | -24.18M | -67.79M | -18.68M | -13.44M | -112.15M |
| Operating Cash Flow | -24.19M | -67.72M | -18.68M | -10.96M | -109.75M |
| Investing Cash Flow | 7.00M | 19.93M | -5.00K | -2.47M | -50.79M |
| Financing Cash Flow | -3.13M | 95.14M | 406.00K | 30.07M | 52.17M |
Q32 Bio Technical Analysis
Neutral
6.11
Price Trends
5.07
Positive
4.02
Positive
3.08
Positive
Market Momentum
0.46
Positive
51.35
Neutral
23.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTTB, the sentiment is Neutral. The current price of 6.11 is below the 20-day moving average (MA) of 6.34, above the 50-day MA of 5.07, and above the 200-day MA of 3.08, indicating a neutral trend. The MACD of 0.46 indicates Positive momentum. The RSI at 51.35 is Neutral, neither overbought nor oversold. The STOCH value of 23.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for QTTB.
Q32 Bio Risk Analysis
Q32 Bio disclosed 82 risk factors in its most recent earnings report. Q32 Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Q32 Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $89.39M | 0.18 | 1630.23% | ― | ― | 49.57% | |
54 Neutral | $75.51M | -4.61 | -10.61% | ― | ― | 45.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $23.24M | -0.45 | -310.89% | ― | ― | 49.43% | |
45 Neutral | $33.18M | -0.97 | -258.37% | ― | ― | 29.95% | |
43 Neutral | $26.13M | -3.81 | -197.68% | ― | ― | 78.60% | |
40 Underperform | $9.26M | -3,346.34 | -526.36% | ― | ― | -2.46% |
* Healthcare Sector Average
QTTB
Q32 Bio
6.38
4.78
298.75%
TPST
Tempest Therapeutics
1.59
-7.75
-82.98%
PDSB
PDS Biotechnology
0.64
-0.42
-39.52%
GRCE
Grace Therapeutics
5.13
2.93
133.18%
CALC
CalciMedica
0.59
-1.25
-68.03%
SNTI
Senti Biosciences
0.86
-2.14
-71.47%
Q32 Bio Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Q32 Bio Launches Flexible $14.2 Million ATM Program
Positive
Mar 27, 2026
On March 27, 2026, Q32 Bio entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald to establish an at-the-market equity program for its common stock. The arrangement allows the company, at its discretion, to sell up to $14...
Business Operations and StrategyPrivate Placements and Financing
Q32 Bio Announces $10.5 Million Registered Direct Offering
Positive
Feb 17, 2026
On February 17, 2026, Q32 Bio Inc. announced it had entered a definitive agreement with institutional investors for a $10.5 million registered direct offering of 1,666,679 shares of common stock and pre-funded warrants to purchase up to 1,025,654 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.